We are live on ! Find out more
PRLD icon

Prelude Therapeutics
PRLD

39 hedge funds and large institutions have $994M invested in Prelude Therapeutics in 2020 Q3 according to their latest regulatory filings, with 39 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

78.48% more ownership

Funds ownership: 0% → 78.48% (+78%)

Holders
39
Holders Change
+39
Holders Change %
–
% of All Funds
0.79%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
39
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$440M
2
BBA
Baker Bros. Advisors
New York
+$286M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$88.3M
4
HA
HHLR Advisors
Cayman Islands
+$21.2M
5
UBS AM
UBS AM
Illinois
+$20.5M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$470M +$440M +15,594,877 New
BBA
2
Baker Bros. Advisors
New York
$305M +$286M +10,118,636 New
Fidelity Investments
3
Fidelity Investments
Massachusetts
$90.1M +$88.3M +3,128,384 New
HA
4
HHLR Advisors
Cayman Islands
$22.6M +$21.2M +750,000 New
UBS AM
5
UBS AM
Illinois
$21.9M +$20.5M +726,463 New
Massachusetts Financial Services
6
Massachusetts Financial Services
Massachusetts
$15.6M +$14.6M +518,011 New
T. Rowe Price Associates
7
T. Rowe Price Associates
Maryland
$12.1M +$11.3M +400,000 New
RSCM
8
Rock Springs Capital Management
Maryland
$10.9M +$10.2M +360,263 New
SCM
9
Suvretta Capital Management
New York
$6.78M +$6.35M +225,000 New
WP
10
Woodline Partners
California
$5.4M +$5.07M +179,361 New
Point72 Asset Management
11
Point72 Asset Management
Connecticut
$4.69M +$4.4M +155,690 New
Federated Hermes
12
Federated Hermes
Pennsylvania
$4.52M +$4.24M +150,000 New
Citadel Advisors
13
Citadel Advisors
Florida
$3.34M +$3.13M +110,915 New
Goldman Sachs
14
Goldman Sachs
New York
$2.51M +$2.35M +83,200 New
BlackRock
15
BlackRock
New York
$1.88M +$1.76M +62,450 New
Legal & General Group
16
Legal & General Group
United Kingdom
$1.85M +$1.74M +61,489 New
Squarepoint
17
Squarepoint
New York
$1.63M +$1.53M +54,066 New
CCM
18
CAAS Capital Management
New York
$1.51M +$1.41M +50,000 New
MIM
19
Monashee Investment Management
Massachusetts
$1.51M +$1.41M +50,000 New
Tudor Investment Corp
20
Tudor Investment Corp
Connecticut
$1.47M +$1.37M +48,624 New
Alyeska Investment Group
21
Alyeska Investment Group
Illinois
$1.37M +$1.28M +45,360 New
Vanguard Group
22
Vanguard Group
Pennsylvania
$1.36M +$1.27M +45,000 New
ZP
23
Zimmer Partners
New York
$1.21M +$1.13M +40,000 New
MWNA
24
Marshall Wace North America
New York
$1.04M +$971K +34,383 New
PCM
25
Pinz Capital Management
New York
$937K +$878K +31,101 New
1
2

PRLD Hedge Fund Activity: Q3 2020 in Review

39 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Prelude Therapeutics (PRLD) for Q3 2020, worth a combined $994M.

Buyers outnumbered sellers: 39 funds opened new PRLD positions and 0 closed out — a net gain of 39 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was OrbiMed, opening a new position worth an estimated $440M.

  • 39 institutional investors held Prelude Therapeutics (PRLD) as of Q3 2020, up from 0 in Q2 2020.
  • Funds reported $994M of Prelude Therapeutics stock for Q3 2020.
  • 39 funds opened new Prelude Therapeutics positions in Q3 2020 and 0 closed out, a net change of +39 holders.
  • The largest Prelude Therapeutics buyer in Q3 2020 was OrbiMed, an estimated $440M added.

Based on aggregated 13F filings for Q3 2020.